{
    "title": "114_hr639",
    "content": "The \"Improving Regulatory Transparency for New Medical Therapies Act\" allows for scheduling of substances included in new FDA-approved drugs, specifying that approval will not take effect until the interim final rule controlling the drug is issued under the Controlled Substances Act. The Secretary will issue a scientific evaluation and recommend controls under the Controlled Substances Act before approving new drugs. Approval will only occur after the interim final rule controlling the drug is issued. The approval of a biological product under the Controlled Substances Act will not take effect until the interim final rule controlling the product is issued. The Secretary notifies the sponsor of intent to issue a scientific evaluation and recommend controls under the Controlled Substances Act. Approval of the application is contingent upon the issuance of an interim final rule for the biological product. The date of approval is determined by the later of the application approval date or the issuance of the interim final rule. The approval date for animal drugs is determined by the later of the application approval date or the issuance of the interim final rule controlling the biological product under the Controlled Substances Act. The approval of a drug under the Controlled Substances Act is contingent upon the issuance of an interim final rule controlling the drug. The approval date is defined as the later of the application approval date or the issuance of the interim final rule. The term 'date of approval' for a drug application is defined as the later of the application approval date or the issuance of the interim final rule controlling the drug. Conditional approval of an application may be delayed until the interim final rule is issued. The Secretary plans to issue a scientific evaluation and recommend controls under the Controlled Substances Act before granting conditional approval for a drug application. The date of approval for such applications is defined as the later of the conditional approval date or the issuance of the interim final rule controlling the drug. The Secretary will issue a scientific evaluation and recommend controls under the Controlled Substances Act before granting conditional approval for a drug application. The approval date is defined as the later of the conditional approval date or the issuance of the interim final rule controlling the drug. The Secretary will issue a scientific evaluation and recommend controls under the Controlled Substances Act before granting conditional approval for a drug application. The drug will not be considered approved until the interim final rule controlling the drug is issued. The Secretary will issue a scientific evaluation and recommend controls under the Controlled Substances Act before granting conditional approval for a drug application. The drug will not be considered approved until the interim final rule controlling the drug is issued in accordance with section 201(j) of the Controlled Substances Act. The Attorney General must issue an interim final rule controlling a drug recommended for scheduling within 90 days of receiving the evaluation and recommendation from the Secretary of Health and Human Services. The Attorney General must issue an interim final rule for a drug recommended for scheduling within 90 days of receiving the evaluation and recommendation from the Secretary of Health and Human Services. The rule becomes immediately effective without needing to demonstrate good cause, providing interested persons with the opportunity to participate. Section 572 of the Federal Food, Drug, and Cosmetic Act requires the Attorney General to issue an interim final rule for a drug recommended for scheduling within 90 days. The rule becomes effective immediately without needing to show good cause, allowing for public comment and hearings before a final rule is issued. Section 156 of title 35, United States Code, is amended to extend the patent term for drug products recommended for controls under the Controlled Substances Act by the Secretary of Health and Human Services. The Secretary of Health and Human Services notifies the sponsor of a drug product application recommended for Controlled Substances Act controls. The drug product is considered approved or indexed under relevant provisions and has permission for commercial marketing or use. The \"covered date\" is determined by the approval or conditional approval date under specific sections of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. The Controlled Substances Act is amended to enhance new drug development by adding provisions for registration to manufacture controlled substances for clinical trials. The covered date for drug approval is determined by specific sections of the Public Health Service Act or Federal Food, Drug, and Cosmetic Act. SEC. 3. ENHANCING NEW DRUG DEVELOPMENT. Amends Section 303 of the Controlled Substances Act to streamline registration for manufacturing controlled substances for clinical trials. Attorney General must register or issue a notice within specific timeframes after application acceptance. SEC. 4. RE-EXPORTATION AMONG MEMBERS OF THE EUROPEAN ECONOMIC AREA. Amends Section 1003 of the Controlled Substances Import and Export Act regarding re-exportation within the European Economic Area. Section 304(c) requires a hearing on the application under section 1008(i) of the Controlled Substances Import and Export Act. Section 1003 is amended to allow re-exportation among members of the European Economic Area. Subsequent to re-exportation within the European Economic Area, controlled substances can be exported between member countries if specific conditions are met. After re-exportation within the European Economic Area, controlled substances can be exported between member countries if specific conditions are met, including documentation certification within 30 days of each re-exportation. After re-exportation within the European Economic Area, controlled substances can be exported between member countries if specific conditions are met, including documentation certification within 30 days of each re-exportation. The Attorney General is limited in promulgating regulations that impede re-exportation of controlled substances among European Economic Area countries. The Attorney General is restricted from creating regulations that hinder the re-exportation of controlled substances among European Economic Area countries, including not imposing time constraints or requiring information prior to exportation. The curr_chunk is about the roles of the Speaker of the House of Representatives and the Vice President of the United States as President of the Senate."
}